interleukin-8 and Blood-Coagulation-Disorders

interleukin-8 has been researched along with Blood-Coagulation-Disorders* in 1 studies

Trials

1 trial(s) available for interleukin-8 and Blood-Coagulation-Disorders

ArticleYear
Cytokine removal by plasma exchange with continuous hemodiafiltration in critically ill patients.
    Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis, 2002, Volume: 6, Issue:6

    The effectiveness of plasma exchange (PE) with continuous hemodiafiltration (CHDF) in the treatment of critically ill patients was evaluated based on changes in cytokine levels. Twenty-six patients with acute hepatic failure were treated with PE (PE group) or PE and CHDF (PE+CHDF group), and the levels of cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, and IL-8 were determined before and after treatment. Bilirubin levels were significantly lower after treatment in both the PE and PE+CHDF groups. There were no significant differences in TNF-alpha levels before and after treatment in the PE group, but the TNF-alpha level was significantly lower after treatment in the PE+CHDF group. There were no significant differences in the IL-6 levels before and after treatment in both the PE and PE+CHDF groups. There were no significant differences in IL-8 levels before and after treatment in the PE group, but the IL-8 level was significantly lower after treatment in the PE+CHDF group. PE with CHDF therapy was given to 5 patients with acutely aggravated autoimmune diseases, 2 patients with hemorrhagic shock and encephalopathy syndrome, and 3 patients with thrombotic microangiopathy. The results suggested that PE with CHDF therapy are useful in critically ill patients with suspected hypercytokinemia.

    Topics: Adult; Aged; Autoimmune Diseases; Bilirubin; Blood Coagulation Disorders; Critical Illness; Cytokines; Female; Hemodiafiltration; Humans; Interleukin-6; Interleukin-8; Liver Failure, Acute; Male; Middle Aged; Plasma Exchange; Shock, Hemorrhagic; Tumor Necrosis Factor-alpha

2002